BioInsights - Optimizing and standardizing apheresis: critical next steps for the cell therapy industry

Optimizing and standardizing apheresis: critical next steps for the cell therapy industry

Cell & Gene Therapy Insights 2020; 6(2), 109-115.

10.18609/cgti.2020.014

Published: 1 April 2020
Interview
Joseph M Roig

Joseph M Roig got his BSc in Chemistry in 1980 (University of Barcelona) and started his professional career at Coulter (Beckman-Coulter nowadays), where he worked in cell counting and flow cytometry. He joined COBE BCT (currently Terumo BCT) in 1991 to help the company start operations in Spain, moving to the US to continue working for the same company in 2000. During the years that he worked for COBE/Terumo BCT he was involved with all existing apheresis variants (donor collections, leukapheresis, therapeutic apheresis) as well as cell processing. He became part of the Terumo BCT Scientific Support group in 2012 and the Medical Affairs group in 2016, the year he got a Masters in Transfusion Medicine and Advanced Cell Therapies (EMTACT) by the Autonomous University of Barcelona. He is currently working as an autonomous cell collections/cell therapy consultant for the industry.